

# PXR Mediated Protection against Liver Inflammation by Ginkgolide A in Tetrachloromethane Treated Mice

Nanhui Ye, Hang Wang, Jing Hong, Tao Zhang, Chaotong Lin and Chun Meng\*

*Institute of Pharmaceutical Biotechnology and Engineering, College of Biological Science and Biotechnology, Fuzhou University, Fuzhou, Fujian, 350108, China*

## Abstract

The pregnane X receptor (PXR), a liver and intestine specific receptor, has been reported to be related with the repression of inflammation as well as activation of cytochrome P450 3A (CYP3A) expression. We examined the effect of PXR on tetrachloromethane (CCl<sub>4</sub>)-induced mouse liver inflammation in this work. Ginkgolide A, one main component of *Ginkgo biloba* extracts (GBE), activated PXR and enhanced PXR expression level, displayed both significant therapeutic effect and preventive effect against CCl<sub>4</sub>-induced mouse hepatitis. siRNA-mediated decrease of PXR expression significantly reduced the efficacy of Ginkgolide A in treating CCl<sub>4</sub>-induced inflammation in mice. Flavonoids, another important components of GBE, were shown anti-inflammatory effect in a different way from Ginkgolide A which might be independent on PXR because flavonoids significantly inhibited CYP3A11 activities in mice. The results indicated that anti-inflammatory effect of PXR might be mediated by enhancing transcription level of IκBα through binding of IκBα. Inhibition of NF-κB activity by NF-κB-specific suppressor IκBα is one of the potential mechanisms of Ginkgolide A against CCl<sub>4</sub>-induced liver inflammation.

**Key Words:** Pregnane X receptor, Liver inflammation, Ginkgolide A, PXR knock-down, IκBα expression

## INTRODUCTION

PXR, known as a xenobiotic sensor, is a nuclear receptor activated by numerous xenobiotic compounds. It was shown to both biochemically and genetically activate expression of CYP3As, CYP2Bs, UGT1A1, ABCB1, and MRP2 to detoxify and clear xenobiotics from the body (Kliwer *et al.*, 1998; Kliwer *et al.*, 2002; Austin *et al.*, 2015). PXR belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. Ligand-activated PXR regulates expression of target genes through heterodimerizing with 9-*cis* retinoic acid receptor alpha (RXRα) to act on promoters.

A few studies have also shown that PXR has potential anti-inflammatory effects. Single-nucleotide polymorphisms linked to a decrease in PXR activity or expression level have resulted in inflammatory bowel disease in patients (Langmann *et al.*, 2004; Dring *et al.*, 2006; Shah *et al.*, 2006; Reyes-Hernandez *et al.*, 2014; Zhang *et al.*, 2014). PXR-null mice were much easier subjected to colitis than wild-type mice (Shah *et al.*,

2006). One possibility of anti-inflammation mechanism is that PXR could afford the intestinal epithelial barrier based on its detoxification properties. The other possibility is involved with cross-talk between PXR and NF-κB signaling pathways (Gu *et al.*, 2006). They reported that p65, one subunit of NF-κB, repressed PXR association with its target genes' promoters through competitively combining RXRα. Inversely PXR activation inhibited the activity of NF-κB in a dependent manner of ligands activation (Zhou *et al.*, 2006).

GBE, one of most commonly used herbal medicines, has been used clinically for curing peripheral vascular diseases in China, France and Germany. The recent research showed that the GBE complex exhibited hepatoprotective effects against carrageenan-induced acute and chronic liver injuries in rats, but the exact hepatoprotective mechanism of GBE was not clear (Abdel-Salam *et al.*, 2004). Previous rodent studies indicated that continuously feeding GBE influenced pharmacokinetics of other drugs, including shortening barbiturate-induced narcosis (Brochet *et al.*, 1999; Kubota *et al.*, 2003) and reducing the hypotensive action of nicardipine (Kubota *et al.*, 2003).

**Open Access** <http://dx.doi.org/10.4062/biomolther.2015.077>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received Jun 11, 2015 Revised Jul 11, 2015 Accepted Oct 2, 2015  
Published online Jan 1, 2016

\*Corresponding Author

E-mail: mengchun@fzu.edu.cn  
Tel: +86 591 22866379, Fax: +86 591 22866379

The reason that GBE effecting pharmacodynamics and pharmacokinetics of drugs was related to activity of cytochrome P450 (P450) enzymes. In rat model GBE increased hepatic expression of CYP2B (Shinozuka *et al.*, 2002; Umegaki *et al.*, 2002), one important member of P450 family. It becomes clear that some components in GBE (including flavonoids and terpene trilactones) are responsible for P450 activities. Moreover some studies on rodent models showed that drug-drug interactions might be mediated by PXR as did in human (Kliwer *et al.*, 2002).

The constitution of GBE used in previous studies was not uniform. For example, levels of the terpene trilactones in the extracts used in Shinozuka and Umegaki studies (Shinozuka *et al.*, 2002; Umegaki *et al.*, 2002) were greater than those in many of the commercially available GBE which contain only 6% terpene trilactones (van Beek, 2002). Shinozuka (Shinozuka *et al.*, 2002) reported that two main components in GBE, bilobalide and Ginkgolide A, played different roles in the modulation of CYP2B1 and CYP3A23 gene expression and enzyme activities in rat model. In this work we investigated effect of PXR on hepatitis and colitis in mice for a more thorough understanding the relationship between PXR and GBE components in anti-inflammation process.

## MATERIALS AND METHODS

### Materials


A standardized powder form of Ginkgolide A and flavonoids were purchased from National Institute for the Control of Pharmaceutical and Biological Products, China. 5-pregnen-3 $\beta$ -ol-20-one-16 $\alpha$ -carbonitrile (PCN), Ips, and nicardipine were purchased from Sigma-Aldrich. All other common reagents not listed were purchased from Sigma-Aldrich or other common vendors.

### Animal experiments

The animal studies were conducted in accordance with the guidelines of the China Council on Animal Care. 4-week-old male C57BL/6 mice (14-16 g) were purchased from the Laboratorial Animal Center of Fujian medical University, China. Mice used in the study were housed 6 per cage and were allowed to acclimate for a period of 3 days prior to the start of the study. Animals were kept in a temperature-controlled facility with 12-h light/dark cycles and were free access to regular rodent chow (commercial rodent diet from the Laboratorial Animal Center of Fujian Medical University) and tap water.

In this work we characterized the development of hepatitis and colitis in mice subjected to CCl<sub>4</sub> gastric perfusion. For induction of hepatitis and colitis, mice received CCl<sub>4</sub> (5 ml/kg each day) for 3 consecutive days using corn oil as vehicle through gastric perfusion, and control mice received corn oils using the same way. Therapeutic mice were treated with different dose Ginkgolide A after they first received CCl<sub>4</sub> for 3 days. Ginkgolide A in corn oil were administered once daily by oral gavage. Preventive group started to receive therapeutic compound 5 days before the induction of hepatitis and colitis. Control mice received oils using the same way. CCl<sub>4</sub>-induced mice received 0.9% NaCl were used as positive model group.

For study of effect of Ginkgolide A on micadipine metabolism, mice were divided into 3 groups (untreated control, Ginkgolide A induction and flavonoids induction). Mice treated with



**Fig. 1.** Plasmid construction with a hairpin used for silencing PXR in mice (The hairpin structure DNA was transcribed with H1 promoter). **AGATCT(BglII)** GAACGCTGACGTCATCAACCCGCTCCAAGGAATCGCGGGCCAGTGTCACTAGGCGGGAACTCCAGCCGCGCGTGGCCCTGGCAGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTGCGTATGTGTTCTGGGAAATCACCATAAACGTGAAATGTCTTTGGATTGGGAATCTTATAAGTTCTGTATGAGACCAC (H1 promoter) **GCTAGC(Nhe)** CCGGACAAGGCCACGCTATTTCCAAGAGA**ATAGCCAGTGGCCTTGTC** TTTTT**GGCC(NOT I)** (Hairpin).

Ginkgolide A, flavonoids were orally dosed once daily for 3 consecutive days using corn oil as vehicle respectively. Control group were treated only with corn oil. After treated with nicardipine by gavage, mice were anesthetized with pentobarbital and get blood from eye socket and sacrificed in different time, and the livers were immediately removed for total RNA isolation (Kubota *et al.*, 2003). The concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in sera were determined by enzymatic assay with RI1000TM autochemical analyzer.

### Macroscopic and histologic assessment of hepatitis and colitis

The livers and colons were examined to evaluate the macroscopic lesions according to the conglutination state among the organs. One part of the liver and colon specimens was fixed overnight in 4% paraformaldehyde and embedded in paraffin. The other parts of the liver and colon were used for mRNA quantification of PXR, TNF $\alpha$  and CYP3A11 (Ameho *et al.*, 1997).

### PXR knocking down mice construction

The PXR knock down mice were created by transfecting PXR-targeting short hairpin RNAs on plasmid pCI(neo) (Fig. 1). The short hairpin RNA designed for knocking down PXR drove by mouse H1 promoter (cloned from HepG2 cells, supplement A) was as follows: 5'-CTAGC CC GGACAAGGCCACTGGCTAT TTCAAGAGA ATAGCCAGTGGCCTTGTCCTTTTTT-3' and 5'-GGCC AAAAAAGGACAAGGCCACTGGCTAT TCTCTTGAA ATAGCCAGTGGCCT TGTCCGGG-3'. The cationic liposome-siRNA complex was prepared by addition of 0.4-1.3 mg/kg of siRNA into 100-150  $\mu$ l of Lipofectamine™ 2000 (total 200  $\mu$ l). The ratio of siRNA to liposome was

**Table 1.** PCR primers used in this article

Name	Direction	Sequence	Product size
β-actin	Forward	GGTCTCAAACATGATCTGGG	238 bp
	Reverse	GGGTCAGAAGGACTCCTATG	
IκBα	Forward	CGTCTTATTGTGGTAGGATCAGC	196 bp
	Reverse	ACCACTGGGGTCAGTCACTC	
Promoter 1 of IκBα	Forward	AGCCCTTATTTCCAAC	197 bp
	Reverse	GCACAAAGAAAGTCCC	
Promoter 2 of IκBα	Forward	AATGCAGGACCTCACA	215
	Reverse	ACAGCAGGCTTTATCC	
PXR	Reverse	TCCAGCGCGCAGCGTGGTA	85 bp
	Reverse	GCAGGATATGGCCGACTACAC	
RXRα	Forward	CTTTGACAGGGTGCTAACAGAGC	172 bp
	Reverse	ACGCTTCTAGTGACGCATACACC	
TNFα	Forward	TCAGCGAGGACAGCAA	279 bp
	Reverse	GCCACAAGCAGGAATG	

1:5 (wt/vol). The liposome-siRNA mixture was injected via the mouse tail vein according to the manufacturer's protocol. The negative control mice were only received blank plasmid PCI mixed with Lipofectamine™ 2000.

#### Determination of mRNA expression

Total RNA was isolated from mouse liver using the Quick-Prep RNA extraction kit (Amersham Biosciences Inc.) according to manufacturer's protocol. cDNA was synthesized from 0.5 μg of RNA using the first strand cDNA synthesis kit (MBI Fermentas). mRNA levels of various genes were determined by semiquantitative real-time PCR using SYBR Green I according to Abi 7300 protocol description. Primers were synthesized by the DNA Synthesis Centre, Sangong, China. Primer sequences for PCR in this research are listed in Table 1. All mRNA levels were normalized to β-actin mRNA. Normalization to actin mRNA was found to give comparable results.

#### EMSA

Nuclear protein extracts from mouse liver cells treated with CCl<sub>4</sub> were prepared for EMSA as described earlier (Gu *et al.*, 2006; Han *et al.*, 2008) with a little change. Nuclear proteins (5 μg) from cells were incubated for 30 min in a reaction mixture containing 40 mM KCl, 1 mM MgCl<sub>2</sub>, 0.1mM EGTA, 0.5mM dithiothreitol, 20 mM Hepes, pH 7.9, 4% Ficoll (400 K) and PCR product of IκBα PCR product 1 contained PXR binding site 1 (-10634--10621) or product 2 contained site 2 (-3164--3151). After incubation for 30 min at room temperature, the reaction mixtures were separated by electrophoresis in 4.0% agarose gel. The gel of each lane was cut into 0.5 cm long to extract DNA for analysis of DNA shift with PCR.

#### Statistical analysis


All studies were performed using n=5. All data are expressed as means ± standard deviation (SD). Statistical significance was analyzed by a one-way ANOVA followed by the Newman-Keuls multiple range test (SPSS version 12.0, SPSS, Inc., Chicago, IL, USA). Single (\*), double (\*\*), and triple (\*\*\*) marks represent statistical significance in  $p < 0.05$ ,  $p < 0.01$  and  $p < 0.001$ , respectively.

## RESULTS


### Therapeutic effect of Ginkgolide A in treating CCl<sub>4</sub>-induced mice hepatitis

Gastric perfusion of CCl<sub>4</sub> led to the adhesion between the liver and the adjacent tissues mediated by white tissue in the positive model mouse group (Fig. 2A). Whereas control group and high dose Ginkgolide A treated group had no macroscopic lesions in both livers and colons. Hematoxylin-eosin-stained liver tissue sections revealed that CCl<sub>4</sub>-induced acute inflammation, massive and severe hepatocyte necrosis at the centrilobular zone of mouse livers (Fig. 2B). The results showed that severe hepatotoxicity and colitis were induced by gastric perfusion of CCl<sub>4</sub> (5 mL/kg) in corn oil (1:1) at a dose of 750 mg/kg/day for 3 days. We also observed the obvious disruption of the sinusoidal and lobular architecture of the liver in the positive model group. Cells exhibited a regular arrangement surrounding the liver tube in normal mouse livers. Administration of CCl<sub>4</sub> induced large areas of liver tissue necrosis and led to most liver cells in an irregular arrangement. Different dose Ginkgolide A (from 50 to 200 mg/kg/day) significantly decreased CCl<sub>4</sub>-induced liver lesions and reduced CCl<sub>4</sub>-induced necroinflammatory response in a dose-dependent manner. There was no obvious necroinflammation in groups treated with high dose Ginkgolide A, and mice liver tissue section slides (paraffin embedded) showed no significant difference between control group and high dose Ginkgolide A treated group.

The levels of ALT and AST, which are mainly distributed in liver cell cytoplasm and mitochondria respectively, were usually very low in sera. When liver cells necrotized, ALT and AST were released from liver cells to sera. So their levels in sera are commonly used as an important indicator of hepatitis. Both AST and ALT in sera of CCl<sub>4</sub>-treated mice showed liver cells and the mitochondria had been severely damaged (Fig. 3). Compared with CCl<sub>4</sub>-treated positive model mice, the levels of AST and ALT significantly decreased in sera of ginkgolide A treated mice in a dose-dependent manner. Liver tissue slides observation (Fig. 4A) and changes of AST and ALT in sera (Fig. 4B, C) showed that Ginkgolide A also exhibited satisfied preventive effect against CCl<sub>4</sub>-induced liver necrosis. Our re-



**Fig. 2.** Therapeutic effect is improved by Ginkgolide A in treating CCl<sub>4</sub>-induced hepatitis mice. (A) Macroscopic appearance of the liver of mice receiving vehicle only (Control), CCl<sub>4</sub>, or mice receiving Ginkgolide A (50, 100, and 200 mg/kg/d) after the administration of CCl<sub>4</sub> (the red arrow showed the adjacent tissues). (B) Representative histological sections of liver tissues. Mice killed 6 d after Ginkgolide A treatment (the red arrows showed the necrosis of livers).



**Fig. 3.** Effect of Ginkgolide A on ALT and AST level in sera of CCl<sub>4</sub>-treated mice. ALT level in sera (A). AST level in sera (B). Control mice receiving vehicle only; model mice receiving CCl<sub>4</sub> (5 ml/kg/d), 1, 2, 3 group of mice receiving Ginkgolide A 50, 100, and 200 mg/kg/d respectively 3d before the administration of CCl<sub>4</sub>. The number of mice is indicated and results are expressed as the mean ± SEM. Animals were killed 6 d after Ginkgolide A treatment.

search showed that Ginkgolide A played an important role in GBE mediated anti-inflammatory reaction.


### PXR expression reduced CCl<sub>4</sub>-induced hepatocyte necrosis in mice

The results showed that feeding Ginkgolide A increased PXR expression levels with a dose-dependent manner in mouse livers (Fig. 5). In order to examine whether the anti-inflammation of Ginkgolide A was mediated by PXR, we investigated the effect of PXR expression levels on CCl<sub>4</sub>-induced hepatocyte necrosis through silencing PXR expression in mouse livers. The expression level of PXR was shown that microRNA silenced PXR gene expression in the mouse liver *in vivo* using tail vein injection (Fig. 6A). PXR mRNA expression was increased in the livers of Ginkgolide A treated hepatitis mice, but less abundantly in livers of PXR-silenced mice. The previous report showed that PXR null mice would have a more proinflammatory stance in the small intestine. Our results of histological examination demonstrated that silence of PXR resulted in spontaneous inflammation in livers as well as intestine inflammation (Fig. 6B). Feeding Ginkgolide A showed no obvious curative effect on hepatitis in PXR-silenced mice. These results indicated that anti-inflammatory response of Ginkgolide A might be mediated through PXR.


### Effects of flavonoids on CYP3A11 activities in mice

We have further investigated whether the anti-inflammatory response of other component in GBE was mediated through PXR. It was reported that flavonoids, another main component in GBE, inhibited human CYP3A4 activity (Ho *et al.*, 2001). We used nicardipine, which is a calcium channel blocker and extensively metabolized by CYP3A type (Shinozuka *et al.*, 2002), as probe drug to determine the effect of flavonoids on the CYP3A11 activities in mice. The metabolism of nicardipine (30 mg/kg, intragastric administration) in controls and drug-treated mice were compared in Fig. 7. The serum concentrations of nicardipine were lower by 43.6% in Ginkgolide A treated group than that in control group. Ginkgolide A accelerated metabolic rate of nicardipine in mice. Oppositely in flavonoids-treated mice the peak plasma concentrations of





**Fig. 4.** Preventive effect is improved by Ginkgolide A in treating CCl<sub>4</sub>-induced hepatitis mice. (A) Representative histological sections of liver tissues of mice receiving vehicle only (Control), CCl<sub>4</sub>, or mice receiving Ginkgolide A (50, 100, 200 mg/kg/d) 6 days before the administration of CCl<sub>4</sub>. No Ginkgolide A treatment after mice receiving CCl<sub>4</sub> and mice killed after CCl<sub>4</sub> treatment in 6 days. (B) ALT and (C) AST level in mice sera (1: 50 mg/kg/d; 2: 100 mg/kg/d; 3: 200 mg/kg/d) (The red arrows showed the necrosis of livers).



**Fig. 5.** Ginkgolide A enhanced PXR expression level in mouse liver tissue. Control mice receiving vehicle only; model mice receiving CCl<sub>4</sub> (5 ml/kg/d), 1, 2, and 3 group of mice receiving Ginkgolide A 50 (1), 100 (2), and 200 (3) mg/kg/d respectively after the administration of CCl<sub>4</sub> 6 days.


nicardipine put off from control's 10 min to 20 min and the peak concentration increased by 30% than control groups. It indicated that flavonoids inhibited activity of CYP3A11 to lower nicardipine metabolic rate.

Interestingly though flavonoid is an inhibitor of CYP3As, it could increase PXR expression levels (Fig. 8A). If anti-inflammation mechanism of Ginkgolide A was dependent on CYP3A mediated by activation of PXR, flavonoids should have no


positive protection results against CCl<sub>4</sub>-induced hepatocyte necrosis in mice livers. But flavonoids also showed satisfying positive effects against CCl<sub>4</sub>-induced acute liver inflammation in both therapeutic group mice and preventive group mice. As shown in Fig. 8B, feeding flavonoids for 6 days caused a significant therapeutic effect against the liver lesions and decreased the serum AST and ALT levels with a dose-dependent manner (Fig. 8C). Histologically, livers from flavonoid-diet mice showed obviously therapeutic results compared with control animals. So we can assume that the hepatitis therapies of Ginkgolide A or flavonoids might be not exclusive based on activation of CYP3As in mice, though PXR played an important role in the anti-inflammation process.

**PXR agonist enhances IκBα expression level through activation of PXR**

NF-κB is a major regulator of inflammatory responses stimulated by pro-inflammatory agents, including tumor necrosis factor, viruses, interleukin-1, and bacteria. NF-κB normally resides in the cytoplasm bound by an inhibitory protein known as IκBα. Since NF-κB acts as a mainly inflammation factor, we tested whether activation of PXR affects NF-κB activity. In mouse liver, Ginkgolide A did not inhibit NF-κB expression. But we found that Ginkgolide A enhanced IκBα expression level in a dose-dependent manner as determined through by real-time RT-PCR analysis (Fig. 9). In PXR-silenced mice, we also found that IκBα expression level significantly decreased. We have found two PXR/RXRα binding sites in upstream regulation region of IκBα and EMSA showed PXR/RXR could bind these sites dependent on ligand activation (Fig. 10). Based on the above, we believed that activation of PXR inhibited inflammation could be mediated by inhibiting NF-κB activities via enhancing expression of IκBα. High level IκBα interacted



**Fig. 6.** PXR expression and histological analysis of liver and Jejunum tissue in PXR silence mice. (A) Comparing PXR expression level in different mouse liver. 1: Control mouse; 2: mouse treated with 100 mg/kg/d Ginkgolide A for 3d; 3: PXR-silencing mouse; 4: PXR-silencing mouse treated with 100 mg/kg/d Ginkgolide A for 3d. (B) Liver cross sections (20×) of control group (1), PXR silence group (2), PXR silence group treated with CCl<sub>4</sub> (3) and CCl<sub>4</sub>-induced PXR silence hepatitis mice treated with ginkgolide A (4) respectively. The outline of liver of PXR silence mice (5). A control mouse (6) compared with a severe dodenal villi destroy in a typical PXR silence mouse (7) and a typical PXR silence mouse treated with Ginkgolide A (8), respectively (The red arrows showed the necrosis of livers).



**Fig. 7.** Plasma concentration-time curves of nicardipine in mouse after orally treated with Ginkgolide A or flavonoids respectively.


with NF-κB might inhibit release of NF-κB which decreased the hepatitis and colitis.

**DISCUSSION**


Abdel-Salam *et al* showed that GBE displayed anti-inflammation efficacy in the acute phase of carrageenan-induced models of acute inflammation in rat (Abdel-Salam *et al.*, 2004). In the present work we have confirmed that both Ginkgolide

A and flavonoids in GBE showed obvious anti-inflammatory effect in CCl<sub>4</sub>-treated mice. The findings made in this study also showed that: 1) PXR exerts an inhibitory effect on the development of liver inflammations; 2) anti-inflammatory effect of Ginkgolide A or flavonoids might not be mediated through CYP3As. Our findings that anti-inflammatory effect of flavonoids independent on CYP3A11 indicated that PXR exerted suppression efficiency through another pathway independent on CYP3A pathways.

PXR-nude mice tended to develop spontaneous colitis, along with a significant increased level of NF-κB (Shah *et al.*, 2006). NF-κB plays a central role in inflammation through its ability to induce transcription of proinflammatory genes (Baldwin, 1996). Gu *et al* reported that NF-κB p65 inhibited transactivation of the corresponded genes through directly interacting with the DNA-binding domain of RXRα and preventing PXR/RXRα from binding to the target DNA sequences (Gu *et al.*, 2006). Shah demonstrated that PXR/RXRα complex could not suppress NF-κB activity through direct inhibition of p50/p65 formation inversely (Shah *et al.*, 2006). IκBα could form dimmer with the NF-κB to inhibit the NF-κB activities. Then NF-κB-IκB complex primarily located in the cytoplasm and blocked the ability of NF-κB to bind to the target DNA sequences through immigrating in cell nuclear. So IκBα exhibited the anti-inflammatory effect through binding NF-κB (Li and Nabel, 1997). NF-κB activation increases expression of the adhesion molecules E-selectin, VCAM-1, and ICAM-1 (Chen *et al.*, 1995), so we observed tissue adhesion phenomena in CCl<sub>4</sub>-induced inflammation mice in this research. Transcrip-



**Fig. 8.** Effect of flavonoids on PXR expression in mouse liver and its therapeutic effect on CCl<sub>4</sub>-induced hepatitis in mice. (A) PXR expression levels in mouse liver treated with vehicle, 100 mg/kg/d ginkgolide A and 100 mg/kg/d flavonoids respectively. (B) liver histological sections of mice treated with vehicle, CCl<sub>4</sub>, and 200 mg/kg/d flavonoids (6 days) after CCl<sub>4</sub> treated. (C) Effect of flavonoids on ALT and AST level in sera of CCl<sub>4</sub>-treated mice. Control mice receiving vehicle only; model mice receiving CCl<sub>4</sub> (5 ml/kg/d), 1, 2, and 3 group of mice receiving flavonoids 50, 100, and 200 mg/kg/d respectively 3d before the administration of CCl<sub>4</sub>. Animals were killed 6 d after flavonoids treatment (The red arrows showed the necrosis of livers).




**Fig. 9.** Effect of PXR activation on IκBα expression level in mouse liver. Control: Control mouse; 1: mouse treated with 50 mg/kg/d Ginkgolide A for 3d; 2: mouse treated with 100 mg/kg/d Ginkgolide A for 3d; 3: PXR-silencing mouse; 4: PXR-silencing mouse treated with 50 mg/kg/d Ginkgolide A for 3d; 5: PXR-silencing mouse treated with 100 mg/kg/d Ginkgolide A for 3d.

tional activation of IκBα mediated through Ginkgolide A or flavonoids attenuated liver inflammation and reduced tissue adhesion through inhibiting expression of NF-κB activated proinflammatory factors.

RXRα is a nuclear receptor which exerts its bioactivities by binding, as homodimers or heterodimers with other partners, to specific sequences in the promoters of target genes and regulating their transcription. We have known that RXRα has been shown to interact with CLOCK, TRIM24, nuclear receptor coactivator 2, NPAS2, POU2F1, ITGB3BP, TATA binding protein, IGF1BP3, nuclear receptor coactivator 3, NRIP1, NCOA6, thyroid hormone receptor beta, retinoic acid receptor alpha, nerve growth factor 1B, TADA3L, BCL3, peroxisome proliferator-activated receptor gamma, PPARGC1A, BRD8, liver X receptor beta, MyoD, farnesoid X receptor, calcitriol receptor, about 95 proteins which are involved in biological functions of cell development, differentiation, proliferation, metabolism, and so on (<http://www.thebiogrid.org/>). Interestingly we found





**Fig. 10.** The effects of Ginkgolide A on the combination of PXR/RXR complex with the consensus DNA sequence of  $\kappa$ B determined by EMSA. Proteins of PXR and RXR were extracted from liver cells nuclear. The effects of Ginkgolide A on the combination between PXR/RXR complex and the consensus DNA sequence of  $\kappa$ B was examined with increasing amount of Ginkgolide A (1 and 3  $\mu$ l; 10 ng/ $\mu$ l) for 30 min (lanes 4 and 5). PCN (2  $\mu$ l; 10 ng/ $\mu$ l) for 30 min (lanes 3) was used as positive control. Lps (2  $\mu$ l; 10 ng/ $\mu$ l) for 30 min (lanes 6) was used in lane 6. Bovine serum albumin (BSA) was used as the negative control. The results were analyzed by semi-quantitative PCR. (A) PXR binding site 1 (-10634--10621); (B) site 2 (-3164--3151).

that activation of some other partners of RXR $\alpha$  also exhibited anti-inflammatory activity, such as liver X receptor, farnesoid X receptor, PPAR, RAR (Devchand *et al.*, 1996; Muller and Bendtzen, 1996; Decula and Cantorna, 2001; Desreumaux *et al.*, 2001; Sheu *et al.*, 2002; Fowler *et al.*, 2003; Liu *et al.*, 2009). Whether other RXR $\alpha$  partners could regulate NF- $\kappa$ B activities to exert anti-inflammatory effect is a very attracted question. We will investigate the potential anti-inflammatory mechanism of PXR in the future work.

## CONFLICT OF INTEREST

No conflict of interest is reported.

## REFERENCES

Abdel-Salam, O. M., Baiuomy, A. R., El-batran, S. and Arbid, M. S. (2004) Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. *Pharmacol. Res.* **49**, 133-142.

Ameho, C., Adjei, A., Harrison, E., Takeshita, K., Morioka, T., Arakaki, Y., Ito, E., Suzuki, I., Kulkarni, A., D. Kawajiri, A. and Yamamoto, S. (1997) Prophylactic effect of dietary glutamine supplementation on

interleukin 8 and tumor necrosis factor a production in trinitrobenzene sulfonic acid induced colitis. *Gut* **41**, 487-493.

Austin, G., Holcroft, A., Rinne, N., Wang, L. and Clark, R. E. (2015) Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells. *Eur. J. Haematol.* **94**, 74-78.

Baldwin, A. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annu. Rev. Immunol.* **14**, 649-683.

Brochet, D., Chermat, R., DeFeudis, F. and Drieu, K. (1999) Effects of single intraperitoneal injections of an extract of *Ginkgo biloba* (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. *Gen. Pharmacol.* **33**, 249-256.

Chen, C., Rosenbloom, C., Anderson, D. and Manning, A. (1995) Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa Balpha phosphorylation. *J. Immunol.* **155**, 3538-3545.

Deluca H. F. and Cantorna, M. T. (2001) Vitamin D: its role and uses in immunology. *FASEB J.* **15**, 2579-2585.

Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M., Englaro, W., Schoonjans, K., Derijard, B., Desvergne, B., Wahli, W. and Chambon, P. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor (PPAR) heterodimer: a basis for new therapeutic strategies. *J. Exp. Med.* **193**, 827-838.

Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J. and Wahli, W. (1996) The PPAR- $\alpha$  leukotriene B4 pathway to inflammation control. *Nature* **384**, 39-43.

Dring, M. M., Trimble, V. I., Keegan, D., Ryan, A. W., Brophy, K. M., Smyth, C. M., Keeling, P. W., O'Donoghue, D., O'Sullivan, M., O'Morain, C., Mahmud, N., Wikstrom, A. C., Kelleher, D. and McManus, R. (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. *Gastroenterology* **130**, 341-348.

Fowler, A. J., Schmuth, M., Kao, J., Fluhr, J. W., Rhein, L., Collins, J. L., Willson, T. M., Mangelsdorf, D. J. and Elias, P. M. (2003) Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. *J. Invest. Dermatol.* **120**, 246-255.

Gu, X., Ke, S., Liu, D., Sheng, T., Thomas, P., Rabson, A., Gallo, M., Xie, W. and Tian, Y. (2006) Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. *J. Biol. Chem.* **281**, 17882-17889.

Han, S., Ritzenthaler, J. D., Zheng, Y. and Roman, J. (2008) PPAR-beta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. *Am. J. Physiol Lung Cell Mol. Physiol.* **294**, 1238-1249.

Ho, P. C., Saville, D. J., Wanwimolruk, S. (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. *J. Pharm. Pharm. Sci.* **4**, 217-227.

Kliwer, S. A., Goodwin, B., Willson, T. M. (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. *Endocr. Rev.* **23**, 687-702.

Kliwer, S. A., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T. and Lehmann, J. M. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* **92**, 73-82.

Kubota, Y., Tanaka, N., Nakamura, K., Kunitomi, M., Umegaki, K. and Shinozuka, K. (2003) Interaction of *Ginkgo biloba* extract (GBE) with hypotensive agent, nicardipine, in rats. *In Vivo* **17**, 409-412.

Langmann, T., Mauerer, R., Schar, I. M., Liebis, G., Zah, n. A., Stremme, I. W. and Schmitz, G. (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. *Gastroenterology* **127**, 26-40.

Li, Z. and Nabel, G. (1997) A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. *Mol. Cell Biol.* **17**, 6184-6190.

Liu, Q., Wang, J. and Harnish, D. C. (2009) Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. *Biochim.*



- Biophys. Res. Commun.* **379**, 476-479.
- Muller K. and Bendtzen K. (1996) 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. *J. Investig. Dermatol. Symp. Proc.* **1**, 68-71.
- Reyes-Hernandez, O. D., Vega, L., Jimenez-Rios, M. A., Martinez-Cervera, P. F., Lugo-Garcia, J. A., Hernandez-Cadena, L., Ostrosky-Wegman, P., Orozco, L. and Elizondo, G. (2014) The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients. *PLoS one* **9**, e99974.
- Shah, Y. M., Ma, X., Morimura, K., Kim, I. and Gonzalez, F. J. (2006) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF- $\kappa$ B target gene expression. *Am. J. Physiol. Gastrointest. Liver Physiol.* **292**, 1114-1122.
- Sheu, M. Y., Fowler, A. J., Kao, J., Schmuth, M., Schoonjans, K., Auwerx, J., Fluhr, J. W., Man, M. Q., Elias, P. M. and Feingold, K. R. (2002) Topical PPAR $\alpha$  activators reduce inflammation in irritant and allergic contact dermatitis models. *J. Invest. Dermatol. Symp. Proc.* **118**, 94-101.
- Shinozuka, K., Kubota, Y., Tanaka, N., Mizuno, H., Yamauchi, J., Nakamura, K., Kunitomo, M. (2002) Feeding of *Ginkgo biloba* extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. *Life Sci.* **70**, 2783-2792.
- Umegaki, K., Sanada, H., Yamada, K., Shinozuka, K. (2002) *Ginkgo biloba* extract markedly induces pentoxifyresorufin O-dealkylase activity in rats. *Jpn. J. Pharmacol.* **90**, 345-351.
- van Beek, T. (2002) Chemical analysis of *Ginkgo biloba* leaves and extracts. *J. Chromatogr. A.* **967**, 21-25.
- Zhang, L., Qiu, F., Lu, X., Li, Y., Fang, W., Zhang, L., Zhou, Y., Yang, L. and Lu, J. (2014) A functional polymorphism in the 3'-UTR of PXR interacts with smoking to increase lung cancer risk in southern and eastern Chinese smoker. *Int. J. Mol. Sci.* **15**, 17457-17468.
- Zhou, C., Nelson, E. L., Grun, F., Verma, S., Sadatrafiei, A., Lin, M., Mallick, S., Forman, B. M., Thummel, K. E. and Blumberg B. (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. *J. Clin. Invest.* **116**, 2280-2289.